BGM Group Ltd revenue by segment BGM

Annual Quarterly

BGM Group Ltd splits its revenue 2 ways in its filings. By operating segments, the largest line in fiscal 2025, which ended Sep 30, 2025 was Diversified Pharmaceutical And Allied Products at $23.6 million, 62% of the total. By sales mix, the largest line in fiscal 2025, which ended Sep 30, 2025 was Diversified Pharmaceutical And Allied Products at $23.6 million, 62% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2025 Sep 30, 2025	FY 2024 Sep 30, 2024	FY 2023 Sep 30, 2023	FY 2022 Sep 30, 2022	FY 2021 Sep 30, 2021	FY 2020 Sep 30, 2020
Revenue	38	25	46	65	57	50
Operating segments
Diversified Pharmaceutical And Allied Products	24 -6.0% share 62.2%	25 share 100.0%	—	—	—	—
Insurance Business	11 share 28.9%	—	—	—	—	—
Ai Solutions	3 share 8.9%	—	—	—	—	—
Sales mix
Diversified Pharmaceutical And Allied Products	24 -6.0% share 62.2%	25 share 100.0%	—	—	—	—
Insurance Business	11 share 28.9%	—	—	—	—	—
Ai Solutions	3 share 8.9%	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: BGM (Nasdaq)
Fiscal year ends: September 30
Incorporated in: Cayman Islands
Headquarters: Chengdu
SEC filer status: Non-accelerated filer, Emerging growth company
SEC CIK: 1779578
Former names: Qilian International Holding Group (until Oct 22, 2024); Qilian International Holding Group Ltd (until Oct 16, 2024)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.